With the deepening of medical research, traditional cancer research and treatment methods can no longer meet the growing demand for individualization. Against this backdrop, the iHuPDX (Individualized Human Patient-Derived Xenograft) model of InnoModels Biotechnology has emerged, bringing a new perspective and solution to the field of cancer research and treatment.
The iHuPDX model is a xenograft technology based on individual patient's tumor cells, which forms individualized transplanted tumors by collecting patient's cancer tissue samples and transplanting them into animals such as mice. This technology can more realistically simulate the tumor environment in the patient's body, providing important support for precision medicine.
First, the iHuPDX model is highly individualized. Each patient's tumor has its own unique biological characteristics and heterogeneity, and the iHuPDX model is able to preserve these original features, enabling researchers to gain a more comprehensive understanding of a patient's tumor characteristics. This highly individualized model provides an important experimental tool for precision medicine and helps develop more personalized treatment plans.
Second, the iHuPDX model can be used to predict drug response. Due to the highly individualized nature of the model, researchers can use the iHuPDX model to test the response of different drugs to a specific patient's tumor. This provides a powerful tool for personalized treatment plan development and is expected to improve treatment success rates. Through drug sensitivity experiments, doctors can predict a patient's response to different drugs so that they can choose the most appropriate treatment plan for the patient.

In addition, the iHuPDX model provides a new perspective for cancer research. Through in-depth study of tumor heterogeneity among different patients, researchers can better understand the diversity and complexity of cancer. This provides important information for the development of individualized therapeutic strategies and helps to advance cancer treatment.
The iHuPDX model from InnoModels Biotechnology has other advantages. First, it retains the heterogeneity of the original tumor tissue, making the model closer to the actual patient. Second, the model has good stability and growth rate, providing a reliable experimental platform for drug development and efficacy assessment. Finally, InnoModels Biotechnology has a stable platform of humanized immune system mouse model (HIS) and human tumor xenograft platform (PDX), which provides comprehensive technical support for tumor and tumor immunopharmacodynamics research.
In conclusion, the iHuPDX model from InnoModels Biotechnology has revolutionized the field of cancer research and treatment. It establishes a highly individualized disease model based on individual patient's tumor cells, providing an important experimental tool for precision medicine. By predicting drug response and studying tumor heterogeneity in depth, the iHuPDX model is expected to increase the success rate of treatment and advance cancer therapy. The continuous innovation and efforts of InnoModels Biotechnology in the field of personalized medicine provide more precise and personalized solutions for medical research and drug development, and bring more hope and possibilities to tumor patients.